Last updated on April 2019

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC to Characterize Risk of Herpetic Infection

Brief description of study

A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC (Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic Infection Among Patients, Close Contacts, and Health Care Providers; and Long-term Safety in Treated Patients

Clinical Study Identifier: NCT02910557

Contact Investigators or Research Sites near you

Start Over

Research Site

Sankt Poelten, Austria
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.